Intelligent Bio Solutions Inc. closed 21.66% higher at $3.3700 on August 17, after Armistice Capital, LLC filed an amended Schedule 13G — a beneficial ownership disclosure required of passive investors holding more than 5% of a company's shares — with the Securities and Exchange Commission. Dollar volume for the session was $779,288 across 2,031 trades.
The filing, dated August 14, 2026, shows that Armistice Capital reports beneficial ownership of 141,397 shares of Intelligent Bio Solutions common stock, representing 5.91% of shares outstanding. The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company. Armistice Capital, LLC acts as the Master Fund's investment manager and, under an Investment Management Agreement, exercises voting and investment power over those shares. Steven Boyd, the managing member of Armistice Capital, is named as a co-reporting person.
The filing is an amendment to a prior Schedule 13G. No earlier share count was included in the current document, so the direction and size of any change from the previous position cannot be determined from this filing alone.
The reporting persons certified that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the company.
The company's free float stands at 2,364,340 shares, equal to 98.9% of shares outstanding. Short volume on the August 17 session was 90,215 shares, representing 63.09% of reported volume for that day.